BioNexus Gene Lab Corp. Other than Temporary Impairment Losses, Investments
BioNexus Gene Lab Corp. (BGLC) reported Other than Temporary Impairment Losses, Investments of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfInvestments · last filed 2025-04-15
- BioNexus Gene Lab Corp. other than temporary impairment losses, investments for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- BioNexus Gene Lab Corp. other than temporary impairment losses, investments for fiscal 2023 was $6.19K.
| Period end | Other than Temporary Impairment Losses, Investments 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-04-15 |
| 2023-12-31 | $6.19K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |